

HB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Miao, et al.

Serial No.: 09/451,939

Filing Date: December 1, 1999

For: Method of Treating Dopaminergic and  
GABA-nergic Disorders




) Art Unit: 1646

) Examiner: Not Yet Assigned

**CERTIFICATE OF MAILING**

I hereby certify that the foregoing document is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231 on May 4, 2000.

  
Jonathan Furtado  
Jonathan Furtado

**RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE RULES**

Applicants submit herewith a revised sequence listing which is fully compliant with the requirements of 37 CFR 1.821 through 1.825, in response to the Notice to Comply with Sequence Rules mailed January 18, 2000. We submit herewith a hard copy of the sequence listing and a computer readable form of the sequence listing (the diskette) as requested.

Additionally, I hereby state that the content of the Sequence Listing and the computer-readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

I further state that this submission, filed in accordance with 37 C.F.R. § 1.821(g), does not include new matter.

We believe that we have appropriately provided for fees due in connection with this submission, however, if there are any other fees due in connection with the filing of this Response, please charge the fees to our **Deposit Account No. 06-1448**.

If there are any questions after review of this paper, the Examiner can contact the undersigned as (617) 832-1754.



May 4, 2000

Patent Group  
Foley, Hoag & Eliot LLP  
One Post Office Square  
Boston, MA 02109-2170  
Tel: (617) 832-1000  
FAX: (617) 832-7000

Respectfully submitted,  
FOLEY, HOAG, & ELIOT

A handwritten signature in black ink, appearing to read "David P. Halstead".

David P. Halstead  
Reg. No. 44,735

# BEST AVAILABLE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	---------------------	-----------------------	---------------------------

09/451,939	12/01/99	MIAD	N ONV-0440.02
------------	----------	------	---------------

PATENT GROUP  
FOLEY HOAG ELIOT LLP  
ONE POST OFFICE SQUARE  
BOSTON MA 02109

026270118

13/18/00  
BOSTON  
NOT ASSIGNED

DUL 3/18/00  
FNU 8-18-00

1646

DATE MAILED:

01/18/00

## NOTICE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

An Application Number and Filing Date have been assigned to this application. The items indicated below, however, are missing. Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file a sequence listing in compliance with 37 CFR 1.821-1.825 to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- 1. This application fails to comply with the requirements of 37 CFR 1.821-1.825.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832 as indicated on the attached marked-up copy of the "Raw Sequence Listing".
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF-Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7. OTHER:

### APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

### FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- For Rules Interpretation, call (703) 308-1123
- For CRF submission help, call (703) 308-4212
- For Patent software help, call (703) 308-6856

  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2-COPY TO BE RETURNED WITH RESPONSE